Corrected: Dr Reddy's delays semaglutide commercial supply due to active ingredient issue
09/07/2026 04:55
CORRECTED-Dr Reddy's delays semaglutide commercial supply due to active ingredient issue Corrects headline and text to say Dr Reddy's will delay semaglutide supply, not production
July 9 (Reuters) - Indian drugmaker Dr Reddy's Laboratories REDY.NS said on Thursday that commercial supplies of semaglutide have been delayed due to an active ingredient-related issue in certain batches.
(Reporting by Kashish Tandon in Bengaluru; Editing by Sherry Jacob-Phillips)
((Kashish.Tandon@thomsonreuters.com; 8800437922;))
Recent news on Dr. Reddy's Laboratories
See all newsDr Reddy's rolls out new generic Ozempic brands to ease Obeda supply hit
Dr Reddy's beats quarterly profit estimate on India market lift (updated)
India's Dr Reddy's beats quarterly profit estimate
Brief: Dr. Reddy's Q2 Consol Net PAT 9.25 Billion Rupees
Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption